Lonza raises CDMO guidance as H1 revenue rises 19% at constant FX

Lonza Group reported robust first-half 2025 results, with revenue rising 19% at constant currency to CHF 3.6 billion and net profit up 29.1%, prompting an upward revision of its full-year 2025 CDMO sales growth forecast to 20-21% and margin to 30-31%. While key segments like Integrated Biologics and Advanced Synthesis performed strongly, Specialized Modalities saw a significant decline. Notably, operational free cash flow decreased by 36.1% and net debt increased to CHF 3.6 billion, raising the net debt to core EBITDA ratio to 1.7, indicating a mixed financial picture despite strong top-line growth and elevated guidance.

Analysis

Lonza Group (LONN) delivered a robust first-half 2025 performance, characterized by a 19% increase in revenue at constant exchange rates to CHF 3.6 billion and a 29.1% rise in net profit to CHF 426 million. This strength prompted an upward revision of its full-year guidance for the critical Contract Development and Manufacturing Organization (CDMO) division, with sales growth now forecast at 20-21% and margins at 30-31%. The growth was primarily driven by the Integrated Biologics segment, which saw revenue surge 39.3%, and the Advanced Synthesis unit, where EBITDA margin expanded significantly to 40.3%. However, this positive momentum is contrasted by notable weaknesses. The Specialized Modalities segment experienced a 9.2% revenue decline and a sharp margin contraction to 17.3%. More critically, the company's financial health indicators present a mixed picture: operational free cash flow before acquisitions fell 36.1% to CHF 189 million, while net debt increased to CHF 3.6 billion, pushing the net debt to core EBITDA ratio up to 1.7. This suggests that the impressive top-line growth is capital-intensive and has, for now, come at the cost of cash generation and increased leverage.

Key Decisions for Investors

• Investors should weigh the strong operational performance and upwardly revised guidance of the core CDMO business against the significant 36.1% decline in operational free cash flow and rising net debt.
• It is prudent to monitor for a turnaround in the underperforming Specialized Modalities segment, as its continued weakness could offset gains from the high-growth Biologics division.
• Keep a close watch on future announcements regarding the planned carve-out of the Capsules & Health Ingredients business, as this strategic move could unlock value and reshape the company's profile.